AGENUS INC: EVENTIDE ASSET MANAGEMENT, LLC discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Eventide Asset Management disclosed a stake exceeding 5% in Agenus Inc. via a Schedule 13G filing with the SEC (accession 0001580642-26-007713). The exact share count and percentage were not specified in the filing headline. The disclosure signals that Eventide has crossed the 5% passive-investor threshold, making it a reportable major holder in the clinical-stage immuno-oncology company. Investors will watch for further 13G amendments or 13D filings that could indicate a shift from passive to activist intent.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Agenus Inc, Eventide Asset Management, LLC